Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,556.37
(
-0.37%
)
US TECH 100
23,546.80
(
0.11%
)
Dow Jones
46,124.06
(
-0.18%
)
Brent Oil
96.48
(
-0.02%
)
Bitcoin
70,788.68
(
0.38%
)
News Focus
News Focus
Post# of 257275
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122807
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: oc631 post# 121546

Thursday, 09/11/2014 10:40:16 AM

Thursday, September 11, 2014 10:40:16 AM

Post# of 257275
Remember Alios? They’re among the companies with an HCV nuke in preclinical development:

http://finance.yahoo.com/news/alios-biopharma-announces-upcoming-rsv-120000004.html

Presentation: Preclinical Characterization of AL-335, a Potent Uridine Based Nucleotide Polymerase Inhibitor for the Treatment of Chronic Hepatitis C

Alios is the company from whom VRTX licensed a pair of preclinical nukes in 2011 (#msg-64166913); both of them failed.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Unleash the power of Level 2

Spot liquidity moves with access to US order books.

Sign Up